Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer
Our data support using different HER2-targeted TKI regimens in sequence, offering additional effective treatment options for patients with HER2+ metastatic breast cancer, including patients with brain metastases.
Authors
- Virginia F. Borges (ORCID: https://orcid.org/0000-0003-1158-7524)
- Stephanie Giangiuli (ORCID: https://orcid.org/0000-0001-6966-8023)
- Elena Shagisultanova (ORCID: https://orcid.org/0000-0003-1389-1116)
- Hannah Parris (ORCID: https://orcid.org/0009-0008-6815-7908)
- Peter Kabos
- Dexiang Gao (ORCID: https://orcid.org/0000-0003-3920-7060)
- Jennifer R. Diamond (ORCID: https://orcid.org/0000-0002-0703-2772)
- Radhika Acharya-Leon
- Long Liu (ORCID: https://orcid.org/0000-0002-9679-9130)
Institutions
- University of Colorado Hospital (US)
- Children's Hospital Colorado (US)
- Advanced Emissions Solutions (United States) (US)
- University of Colorado Cancer Center (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Clinical Breast Cancer
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1016/j.clbc.2025.06.004
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09